Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4954 in Healthy Participants and Participants With Dyslipidemia
NCT06980428Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD4954 in dyslipidemia (20 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with Adverse Events and Serious Adverse Events. Started May 2025; status: recruiting.
02
Drugs
AZD4954
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06980428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980428.